Literature DB >> 24129226

Clinical significance of proliferative inflammatory atrophy in prostate biopsy.

A Celma1, P Servián2, J Planas2, J Placer2, M T Quilez3, M A Arbós3, I de Torres4, J Morote5.   

Abstract

INTRODUCTION: Proliferative inflammatory atrophy (PIA) is a frequently observed lesion in prostate biopsies and some authors have postulated its involvement in prostate carcinogenesis. However, the mechanisms that would permit its neoplastic transformation and the clinical significance of its finding in a prostate biopsy is currently not well known.
OBJECTIVE: To analyze the characteristics of the PIA lesion, its possible role in prostate carcinogenesis and its relation with the tumor aggressiveness. MATERIAL AND
METHOD: A systematic review was made of the literature in PubMed with the terms «proliferative inflammatory atrophy» or «PIA» and «prostate.» The most important findings are summarized in accordance with the study objective.
RESULTS: PIA seems to be involved in prostate carcinogenesis. This hypothesis is based on its frequent association to cancer lesions (CaP) and on some genetic alterations that are common to the high grade prostatic intraepithelial neoplasia (HGPIN) and to the CaP, fundamentally deficit in GSTP1 expression and overexpression of AGR2. Currently, there are no epidemiological studies that evaluate the incidence of PIA or its association with HGPIN and CaP. Only one study, carried out by our group, has determined the global incidence of PIA in 30% of the prostate biopsies, a lower association to CaP than the HGPIN lesion and an association between PIA and tumors of lower and insignificant grade.
CONCLUSIONS: PIA shares genetic alterations with HGPIN and CaP. Currently, there is no epidemiologic evidence to consider that the PIA is associated to a greater incidence of CaP and the genetic and epidemiological data available suggest its association to not very aggressive tumors.
Copyright © 2013 AEU. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Agresividad tumoral; Atrofia proliferativa inflamatoria; Cáncer de próstata; Proliferative inflammatory atrophy; Prostate cancer; Tumor aggressiveness

Mesh:

Year:  2013        PMID: 24129226     DOI: 10.1016/j.acuro.2013.04.008

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  4 in total

1.  The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens.

Authors:  D M Moreira; D M de O Freitas; J C Nickel; G L Andriole; R Castro-Santamaria; S J Freedland
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-06-06       Impact factor: 5.554

Review 2.  Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach.

Authors:  Božo Krušlin; Davor Tomas; Tihana Džombeta; Marija Milković-Periša; Monika Ulamec
Journal:  Front Oncol       Date:  2017-04-25       Impact factor: 6.244

Review 3.  Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer.

Authors:  Gianluigi Taverna; Mauro Seveso; Guido Giusti; Rodolfo Hurle; Pierpaolo Graziotti; Sanja Stifter; Maurizio Chiriva-Internati; Fabio Grizzi
Journal:  Curr Gerontol Geriatr Res       Date:  2014-03-19

Review 4.  From Inflammation to Prostate Cancer: The Role of Inflammasomes.

Authors:  Dev Karan; Seema Dubey
Journal:  Adv Urol       Date:  2016-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.